Identification of the molecular lesion in Caenorhabditis elegans mutants isolated through forward genetic screens usually involves time-consuming genetic mapping. We used Illumina deep sequencing technology to sequence a complete, mutant C. elegans genome and thus pinpointed a single-nucleotide mutation in the genome that affects a neuronal cell fate decision. This constitutes a proof-of-principle for using whole-genome sequencing to analyze C. elegans mutants.
|Original language||English (US)|
|Number of pages||3|
|State||Published - 2008|
Bibliographical noteFunding Information:
We thank C.T. Lawley (Illumina, Inc.) for generously producing the paired-end read data described in the manuscript, Q. Chen for performing microinjection, Hobert lab members for comments on the manuscript and the Caenorhabditis Genetics Center for providing the N2 strain. This work was funded by the Howard Hughes Medical Institute, the Muscular Dystrophy Association and the US National Institutes of Health (R01NS039996-05; R01NS050266-03 to O.H., F31 predoctoral grant NS054540-01 to S.S. and U54 CA121852-03 to I.P.).